LungLife AI, Inc. (GB:LLAI) has released an update.
LungLife AI, Inc. has reported significant achievements in the first half of 2024, with the successful clinical validation of their LungLB® test, a leading diagnostic solution for early detection of lung cancer. The company has completed major milestones including regulatory approvals, securing a National Medicare price, and initiating commercial readiness activities like the Early Access Program and marketing campaigns. With a restructuring to control costs and the appointment of an advisor for strategic partnerships, LungLife AI is rapidly advancing towards commercialization of LungLB®, which is now included on the National Cancer Institute’s list of biomarker tests.
For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.
